|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
In this study, IQGAP1 expression was partially silenced in human hepatocellular carcinoma (HepG2) cells.
|
27488117 |
2016 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
IQGAP1 expression was higher in primary HCC (122/150, 81.3%) than matched adjacent tissues (30/150, 20%, p<0.001), whereas IQGAP2 was lower (31/150, 20.7% as compared to 112/150, 74.7%, P<0.001).
|
24998570 |
2014 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
In the current study we extend these findings, and investigate IQGAP1 and IQGAP2 expression in human HCC.
|
20977743 |
2010 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Similarly, immunohistochemical staining of 82 HCC samples showed that IQGAP2 protein expression was reduced in 64/82 (78.0%), while IQGAP1 was present in 69/82 (84.1%).
|
20977743 |
2010 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of miR-124 or miR-203 in HCC cells lacking their expression inhibited cell growth, with direct downregulation of possible targets, cyclin-dependent kinase 6 (CDK6), vimentin (VIM), SET and MYND domain containing 3 (SMYD3) and IQ motif containing GTPase activating protein 1 (IQGAP1) or ATP-binding cassette, subfamily E, member 1 (ABCE1), respectively.
|
19843643 |
2010 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Overexpressing IQGAP1 raised the in vivo tumorigenicity of hepatocellular carcinoma cells, and forced overexpression of IQGAP1 in vitro stimulated cell proliferation.
|
20530982 |
2010 |
|
Brain Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Malignant neoplasm of brain
|
0.300 |
Biomarker
|
disease |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Benign neoplasm of brain, unspecified
|
0.300 |
Biomarker
|
disease |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Brain Tumor, Primary
|
0.300 |
Biomarker
|
disease |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Recurrent Brain Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Primary malignant neoplasm of brain
|
0.300 |
Biomarker
|
disease |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Neoplasms, Intracranial
|
0.300 |
Biomarker
|
group |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Weight Gain
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.
|
19030233 |
2008 |
|
Eczema
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Multiple Sclerosis
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
We suggest that such cis-acting mechanisms may contribute to the multiple sclerosis association of single nucleotide polymorphisms at IKZF3 and IQGAP1.
|
27080863 |
2016 |
|
Multiple Sclerosis
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
|
24076602 |
2013 |
|
Eczema
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
A number of genes, including CC chemokine receptor 4, T cell-specific tyrosine kinase (Emt/Itk), integrin beta1, integrin alpha6, IQGAP1 and MAR/SAR DNA-binding protein (SATB1), were shown to be more highly expressed in patients with moderate and/or severe AD than in controls or patients with mild AD.
|
12483038 |
2002 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed a combination of <i>in vitro</i> studies using human cancer cell lines treated with a cell-permeable peptide that interferes with IQGAP1's ability to bind to PI3K, and <i>in vivo</i> studies utilizing mice genetically knocked out for the <i>Iqgap1</i> (<i>Iqgap1</i><sup>-/-</sup>).
|
31597661 |
2020 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data demonstrate that IQGAP1 contributes to head and neck carcinogenesis.
|
31597661 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed a combination of <i>in vitro</i> studies using human cancer cell lines treated with a cell-permeable peptide that interferes with IQGAP1's ability to bind to PI3K, and <i>in vivo</i> studies utilizing mice genetically knocked out for the <i>Iqgap1</i> (<i>Iqgap1</i><sup>-/-</sup>).
|
31597661 |
2020 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data illustrate that the IQ3 region of IQGAP1 is a promising therapeutic target for PI3K-driven cancer.
|
31235839 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, we report that transgenic GLK promotes tumor metastasis and cell migration through the scaffold protein IQ motif-containing GTPase-activating protein 1(IQGAP1).
|
31431460 |
2019 |